Astria Therapeutics (ATXS) Consolidated Net Income: 2017-2018
Historic Consolidated Net Income for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$5.9 million.
- Astria Therapeutics' Consolidated Net Income fell 6.65% to -$5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.0 million, marking a year-over-year increase of 5.05%. This contributed to the annual value of -$26.0 million for FY2018, which is 4.93% up from last year.
- Latest data reveals that Astria Therapeutics reported Consolidated Net Income of -$5.9 million as of Q4 2018, which was down 1.27% from -$5.8 million recorded in Q3 2018.
- In the past 5 years, Astria Therapeutics' Consolidated Net Income registered a high of -$5.5 million during Q4 2017, and its lowest value of -$7.9 million during Q1 2017.
- Over the past 2 years, Astria Therapeutics' median Consolidated Net Income value was -$6.8 million (recorded in 2017), while the average stood at -$6.7 million.
- Over the last 5 years, Astria Therapeutics' Consolidated Net Income had its largest YoY gain of 16.70% in 2018, and its largest YoY loss of 6.65% in 2018.
- Quarterly analysis of 2 years shows Astria Therapeutics' Consolidated Net Income stood at -$5.5 million in 2017, then dropped by 6.65% to -$5.9 million in 2018.
- Its Consolidated Net Income was -$5.9 million in Q4 2018, compared to -$5.8 million in Q3 2018 and -$6.6 million in Q2 2018.